简介：目的：评价七叶洋地黄双苷滴眼液治疗近视患者准分子激光原位角膜磨镶术（1aseffnsitukeratomileusis，LASIK）后视疲劳的临床疗效。方法：对200例400眼近视患者行LASIK手术，随机分成两组。100例为试验组应用七叶洋地黄双苷滴眼液，另100例为对照组应用潇莱威滴眼液。分别于手术前、用药后1，2，4wk评估患者术后视疲劳的症状和体征，同时观察药物不良反应。结果：随着术后时间的延长，试验组和对照组近视患者视疲劳症状逐渐缓解，在术后1，2wk时，试验组的视疲劳评分低于对照组，两组差异有统计学意义（t=3．160，P=0．001；t=2．727，P=0．0025）；术后4wk时，两组的差异无统计学意义（t=1．423，P=0．10）。结论：随着观察时间的延长，LASIK术后患者视疲劳症状可逐渐得到恢复和改善，七叶洋地黄双苷滴眼液对改善LASIK术后早期视疲劳症状有效。

简介：目的观察七叶洋地黄双苷滴眼液（施图伦）对青少年低度数近视及视疲劳症状的治疗效果。方法收集于2015年6月至9月就诊于浙江省台州医院眼科门诊的青少年近视患者120例240眼,根据用药情况不同随机分为对照组,托吡卡胺组,施图伦组,每组40例80眼,分别比较三组用药前与用药后一月的裸眼视力与屈光状态,根据视疲劳问卷调查表评估用药前后的视疲劳症状变化。结果（1）裸眼视力：施图伦组及托吡卡胺组较治疗前裸眼视力均有一定程度提高,差异有统计学意义（P〈0.05）。（2）近视度数：施图伦组较治疗前矫正度数下降,差异有统计学意义（P〈0.05）,托吡卡胺组矫正度数较治疗前有下降,差异有统计学意义（P〈0.05）。对照组矫正度数较治疗前对比无差异。（3）视疲劳症状：施图伦组视疲劳症状改善37例,总改善率达92.5%。对照组及托吡卡胺组对比治疗前差异无统计学意义。结论施图伦滴眼液能显著改善近视患者的视疲劳症状,对于低度数近视有一定的治疗作用。

简介：AIM:Topresenttheoutcomeofmodifiedgridlaserphotocoagulation(GLP)indiffusediabeticmacularedema(DDME)ineyeswithoutextrafovealand/orvitreofovealtraction.METHODS:InclusioncriteriafortheretrospectivestudywereDDMEeyesofpatientswithtypeⅡdiabetesmellitusthathad≥4monthsoffollow-upfollowingGLP.Onlyoneeyeperpatientwasanalyzed.Using3-Dspectral-domainopticalcoherencetomography(3-DSDOCT),eyesthathadeitherextrafovealorvitreofovealtraction,orhadbeenpreviouslytreatedbyanintravitrealmedication(s)wereexcluded.TreatedDDMEeyesweredividedinto4groups:A)'Classic'DDMEthatinvolvedthecentralmacula;B)edemadidnotinvolvethemacularcenter;C)eyesassociatedwithcentralepiretinalmembrane(ERM);D)DDMEthatwasassociatedwithmacularcapillarydropout≥2disc-diameter(DD).RESULTS:GLPoutcomein35DDMEeyesafter4-24(mean,13.1±6.9)monthswasasfollows:GroupA)18eyeswith'classic'DDME.Followingoneor2(mean,1.2)GLPtreatments,best-correctedvisualacuity(BCVA)improvedby1-2Snellenlinesin44.4%(8/18)ofeyes,andworsenedby1linein11.1%(2/18).Centralmacularthickness(CMT)improvedby7%-49%(mean,26.6%)in77.8%(14/18)ofeyes.CausesofCMTworsening(n=4)werecommonlyexplainable,predominantly(n=3)associatedwithemergenceofextrafovealtraction,5-9monthspost-GLP.GroupB)GLP(s)inDDMEthatdidnotinvolvethemacularcenter(n=6)resultedinimprovedBCVAby1-2linesin2eyes.However,thecentralmaculabecameinvolvedintheedemaprocessaftertheGLPin3(50%)eyes,associatedwithanemergenceofextrafovealtractioninoneoftheseeyes4monthsfollowingtheGLP.GroupC)GLPfailedinall5eyesassociatedwithcentralERM.GroupD)GLPwasofpartialbenefitin2of6treatedeyeswithmacularcapillarydropout≥2DD.CONCLUSION:EyeswithDDMEthatinvolvedthemacularcenterwerefoundtoachievefavourableoutcomesafterGLP(s)duringmid-termfollow-up,unlesscomplicatedpre-GLPorpost-GLPbyvltreoretinalinterfaceabnormalities,oftenextrafovealtra